Results 161 to 170 of about 5,990,883 (357)

Maintaining diversity in America's transit-rich neighborhoods: tools for equitable neighborhood change [PDF]

open access: yes
In some newly transit-rich neighborhoods (TRNs), a new station can set in motion a cycle of unintended consequences in which core transit users—such as renters and low-income households—are priced out of the neighborhood in favor of higher-income, car ...
Barry Bluestone   +2 more
core  

Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer

open access: yesMolecular Oncology, EarlyView.
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh   +5 more
wiley   +1 more source

GENDER GAP IN PRESTIGIOUS ACADEMIC MEETINGS AND LEADERSHIPS – A SURVEY OF THE 9TH IBRO WORLD CONGRESS OF NEUROSCIENCE

open access: yesIBRO Neuroscience Reports, 2023
Eliane Volchan   +8 more
doaj   +1 more source

Diversity [PDF]

open access: yesJournal of Thrombosis and Haemostasis, 2016
F R, Rosendaal, P H, Reitsma
openaire   +5 more sources

Nicotinamide N‐methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling

open access: yesMolecular Oncology, EarlyView.
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou   +5 more
wiley   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham   +21 more
wiley   +1 more source

Nouvelles Diverses

open access: yes, 1876
Transcript of NOUVELLES DIVERSES by Auguste Morel signed A. M., appearing in LE MÉNESTREL, 10 avril 1881, p. 150.
openaire  

Home - About - Disclaimer - Privacy